Liquid chromatographic and mass spectrometric analysis of human serum acid alpha-1-glycoprotein.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 15236441)

Published in Biomed Chromatogr on June 01, 2004

Authors

T Kremmer1, E Szöllösi, M Boldizsár, B Vincze, K Ludányi, T Imre, G Schlosser, K Vékey

Author Affiliations

1: National Institute of Oncology, Department of Biochemistry, PO Box 21, H 1122 Budapest, Hungary. kremmer@oncol.hu

Articles by these authors

In vitro food-drug interaction study: Which milk component has a decreasing effect on the bioavailability of ciprofloxacin? J Pharm Biomed Anal (2009) 1.46

Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol (2005) 1.41

Xenopus Eya1 demarcates all neurogenic placodes as well as migrating hypaxial muscle precursors. Mech Dev (2001) 1.00

Limb development in a "nonmodel" vertebrate, the direct-developing frog Eleutherodactylus coqui. J Exp Zool (2001) 0.92

Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol (1993) 0.90

MassKinetics: a theoretical model of mass spectra incorporating physical processes, reaction kinetics and mathematical descriptions. J Mass Spectrom (2001) 0.87

Antibiotic GE2270 a: a novel inhibitor of bacterial protein synthesis. II. Structure elucidation. J Antibiot (Tokyo) (1991) 0.86

Molecular manipulation with the arthritogenic epitopes of the G1 domain of human cartilage proteoglycan aggrecan. Clin Exp Immunol (2005) 0.84

Application of the fast protein liquid chromatographic system and MonoQ HR 5/5 anion exchanger to the separation of nucleotides. J Chromatogr (1989) 0.84

Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. II. Structure elucidation. J Antibiot (Tokyo) (1996) 0.84

Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines. Cancer Detect Prev (1996) 0.82

Proteinase inhibitors from desert locust, Schistocerca gregaria: engineering of both P(1) and P(1)' residues converts a potent chymotrypsin inhibitor to a potent trypsin inhibitor. Biochim Biophys Acta (1999) 0.82

Formation of a2+ ions of protonated peptides. An ab initio study. Rapid Commun Mass Spectrom (2000) 0.82

Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res (1998) 0.82

Fast atom bombardment mass spectrometry of some lantibiotics. Biol Mass Spectrom (1994) 0.81

Microheterogeneity characterization of a paracelsin mixture from Trichoderma reesei using high-energy collision-induced dissociation tandem mass spectrometry. Rapid Commun Mass Spectrom (1997) 0.79

Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships. J Med Chem (1997) 0.78

FDG PET imaging in hereditary thyroid cancer. Eur J Surg Oncol (2003) 0.78

Teicoplanin metabolism in humans. Antimicrob Agents Chemother (1992) 0.78

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc Natl Acad Sci U S A (1999) 0.78

Potentiation of antimetabolite action by dibromodulcitol in cell culture. Adv Enzyme Regul (1985) 0.78

Characterization of chiral host-guest complexation in fast atom bombardment mass spectrometry. Anal Chem (1996) 0.78

Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol (2002) 0.78

Differentiation of vegetable oils by mass spectrometry combined with statistical analysis. Rapid Commun Mass Spectrom (2002) 0.77

Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity. Biomed Pept Proteins Nucleic Acids (1996) 0.77

Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer (2003) 0.77

Sequence determination of actagardine, a novel lantibiotic, by homonuclear 2D NMR spectroscopy. J Antibiot (Tokyo) (1990) 0.76

Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med Chem (2007) 0.76

Hormonal effects of toremifene in breast cancer patients. J Steroid Biochem (1990) 0.76

Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res (1999) 0.75

Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology (1986) 0.75

Field desorption mass spectrometry of large multiply branched saturated hydrocarbons. J Mass Spectrom (2001) 0.75

Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer (1994) 0.75

[Trends in the hormonal therapy of thyroid cancer]. Orv Hetil (1989) 0.75

Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues. Cell Prolif (2000) 0.75

Qualitative and quantitative determination of poloxamer surfactants by mass spectrometry. Rapid Commun Mass Spectrom (2001) 0.75

Changes in the polyamine and nucleotide metabolism of P388 leukemia cells treated with DL-alpha-difluoromethylornithine in culture. Exp Cell Biol (1988) 0.75

[Clinical significance of steroid receptors in breast cancer]. Orv Hetil (1994) 0.75

Lipoprotein (a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population. Clin Investig (1993) 0.75

Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest (2000) 0.75

In vivo effects of DL-alpha-difluoromethylornithine on the polyamine and nucleotide phosphate metabolism in P388/S leukemia cells. Exp Cell Biol (1986) 0.75

Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate. Bioconjug Chem (1997) 0.75

Comparison of high-performance ion-exchange and ion-pair liquid chromatographic methods for the separation of tumour cell nucleotides. J Chromatogr (1987) 0.75

Mechanistic studies of dUTPases. Nucleosides Nucleotides Nucleic Acids (2004) 0.75

Hydrophobic interaction chromatography of human serum alpha1-antitrypsin and alpha1-acid glycoprotein. J Chromatogr B Biomed Sci Appl (2000) 0.75

[Data on the effect of a low carbon monoxide content in the air on man]. Zentralbl Arbeitsmed (1970) 0.75

Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma (2002) 0.75

Postoperative thyroglobulin level determination to follow up patients with highly differentiated thyroid cancer. Oncology (1989) 0.75

In vitro and in vivo metabolisms of K-48. Anal Bioanal Chem (2007) 0.75

[Detection of osteoid tissues and degenerated intercellular bone substance using a modification of the hematoxylin-cosin staining technique (author's transl)]. Zentralbl Allg Pathol (1974) 0.75

[Method for histochemical study of bone tissue]. Acta Histochem (1972) 0.75

A systematic study of protein labeling by fluorogenic probes using cysteine targeting vinyl sulfone-cyclooctyne tags. Org Biomol Chem (2016) 0.75

[Serum acid alpha-1-glycoprotein (APG) levels in gastrointestinal tumors]. Orv Hetil (1998) 0.75

Investigation of atrazine metabolism in river sediment by high-performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom (2001) 0.75

Analysis of pyridinium aldoximes - a chromatographic approach. Curr Med Chem (2008) 0.75

Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines. Anticancer Drugs (1999) 0.75

[Irradiation proctitis]. Orv Hetil (1977) 0.75

Influence of antiestrogen drugs on the sex hormone and sex hormone-binding globulin levels in breast cancer patients. Ann N Y Acad Sci (1988) 0.75

High-performance liquid chromatographic determination of the plasma concentration of K-27, a novel oxime-type cholinesterase reactivator. J Chromatogr A (2006) 0.75

A re-evaluation of the lipid-bound sialic acid determination. Clin Chim Acta (1991) 0.75

[Mass spectrometry in the verification of pyrimethamine poisoning]. Orv Hetil (1998) 0.75

[Screening of families of patients with medullary cancer of the thyroid]. Orv Hetil (1982) 0.75

[The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients]. Orv Hetil (1991) 0.75

[Developmental process of elementary-school children in the Great Hungarian plain]. Z Gesamte Hyg (1974) 0.75

HPLC analysis of K-48 concentration in plasma. Anal Bioanal Chem (2006) 0.75

Secondary structure of peptide ions in the gas phase evaluated by MIKE spectrometry. Relevance to native conformations. Methods Mol Biol (2000) 0.75

Comparative studies on the polyamine metabolism and DFMO treatment of MCF-7 and MDA-MB-231 breast cancer cell lines and xenografts. Anticancer Res (1992) 0.75

Application of overpressured layer chromatography combined with digital autoradiography and mass spectrometry in the study of deramciclane metabolism. J AOAC Int (1999) 0.75

[Follow up of thyroglobulin levels in patients with surgically treated, highly differentiated thyroid cancer]. Orv Hetil (1989) 0.75

Characterization and differentiation of heterocyclic isomers. tandem mass spectrometry and molecular orbital calculations on 3-methylisoxazolo- and 2-methyloxazolopyridines. J Am Soc Mass Spectrom (1995) 0.75

[Significance of estradiol-progesterone levels in breast tissue in the management of breast cancer]. Orv Hetil (1983) 0.75